Bayer to partner on reversing bleeding from Xarelto

FRANKFURT Tue Feb 5, 2013 9:50am EST

Related Topics

FRANKFURT (Reuters) - German drugmaker Bayer said on Tuesday it planned to collaborate with U.S. peer Portola Pharmaceuticals to study several drugs that reverse the effects of its blood-thinner Xarelto.

Bayer said it expected to complete the study in the second half of this year.

Dangerous bleeding is one of the main risks of bloodthinners such as Xarelto, which are used against thrombosis or heart attacks, and drugs can be applied more widely if they have so-called "antidotes".

U.S. regulators last June rejected the use of Xarelto to prevent heart attacks and strokes in patients with acute coronary syndrome (ACS), citing the risk of bleeding.

Bayer said in September its development partner Johnson & Johnson had filed a response to the regulators' concerns.

(Reporting By Peter Dinkloh; Editing by David Cowell)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

A tourist takes a plunge as she swims at Ngapali Beach, a popular tourist site, in the Thandwe township of the Rakhine state, October 6, 2013. Picture taken October 6, 2013. REUTERS/Soe Zeya Tun (MYANMAR - Tags: SOCIETY) - RTR3FOI0

Where do you want to go?

We look at when to take trips, budget considerations and the popularity of multigenerational family travel.   Video